Aequus Pharmaceuticals Inc. (AQSZF)
- Previous Close
0.0127 - Open
0.0127 - Bid --
- Ask --
- Day's Range
0.0127 - 0.0127 - 52 Week Range
0.0079 - 0.0400 - Volume
1,000 - Avg. Volume
5,966 - Market Cap (intraday)
2.424M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 28, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.aequuspharma.ca--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AQSZF
Performance Overview: AQSZF
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AQSZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AQSZF
Valuation Measures
Market Cap
2.42M
Enterprise Value
5.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.01
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-126.92%
Return on Equity (ttm)
--
Revenue (ttm)
254.9k
Net Income Avi to Common (ttm)
-2.96M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
215.05k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.25M
Research Analysis: AQSZF
Company Insights: AQSZF
AQSZF does not have Company Insights